<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586010</url>
  </required_header>
  <id_info>
    <org_study_id>GN41851</org_study_id>
    <secondary_id>2019-004857-10</secondary_id>
    <nct_id>NCT04586010</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS)</brief_title>
  <acronym>FENhance</acronym>
  <official_title>A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Adult Patients With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of fenebrutinib on disability progression and&#xD;
      relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to&#xD;
      either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a&#xD;
      positive benefit-risk result in the Primary Analysis of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">November 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor will also be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of composite 12-week confirmed disability progression (cCDP12)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of composite 24-week confirmed disability progression (cCDP24)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of 12-week confirmed disability progression (CDP12)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of 24-week confirmed disability progression (CDP24)</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of T1Gd+ lesions, new and/or enlarging T2-weighted lesions as detected by MRI</measure>
    <time_frame>Baseline, Weeks 12, 24, 48 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Brain Volume from Week 24 as assessed by MRI</measure>
    <time_frame>From Week 24 to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Participant-Reported Physical Impacts of Multiple Sclerosis (MS)</measure>
    <time_frame>Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and 96</time_frame>
    <description>Measured by the Multiple Sclerosis, 29-Item [MSIS-29] physical scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of 12-week confirmed 4-point worsening in Symbol Digit Modality Test (SDMT) score</measure>
    <time_frame>Minimum of 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 48 in the Concentration of Serum Neurofilament Light chain (NfL)</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of fenebrutinib at specified timepoints</measure>
    <time_frame>Up to 3.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">736</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>fenebrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral fenebrutinib with teriflunomide-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>teriflunomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive oral teriflunomide with fenebrutinib-matching placebo in a blinded fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenebrutinib</intervention_name>
    <description>Participants will receive fenebrutinib.</description>
    <arm_group_label>fenebrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriflunomide</intervention_name>
    <description>Participants will receive teriflunomide.</description>
    <arm_group_label>teriflunomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.</description>
    <arm_group_label>fenebrutinib</arm_group_label>
    <arm_group_label>teriflunomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score of 0 - 5.5 at screening.&#xD;
&#xD;
          -  A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria.&#xD;
&#xD;
          -  Ability to complete the 9-Hole Peg Test (9-HPT) for each hand in &lt; 240 seconds.&#xD;
&#xD;
          -  Ability to perform the Timed 25-Foot Walk Test (T25FWT) in &lt;150 seconds.&#xD;
&#xD;
          -  For female participants of childbearing potential: agreement to remain abstinent&#xD;
             (refrain from heterosexual intercourse) or use contraceptive measures, and refrain&#xD;
             from donating eggs.&#xD;
&#xD;
          -  For male participants: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse) or use contraceptive measures, and refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease duration of &gt; 10 years from the onset of symptoms and an EDSS score at&#xD;
             screening &lt; 2.0.&#xD;
&#xD;
          -  Female participants who are pregnant or breastfeeding, or intending to become&#xD;
             pregnant.&#xD;
&#xD;
          -  Male participants who intend to father a child during the study.&#xD;
&#xD;
          -  A diagnosis of PPMS or non-active SPMS.&#xD;
&#xD;
          -  Any known or suspected active infection at screening, including but not limited to a&#xD;
             positive screening tests for Hepatitis B and C, an active or latent or inadequately&#xD;
             treated infection with tuberculosis (TB), a confirmed or suspected progressive&#xD;
             multifocal leukoencephalopathy (PML).&#xD;
&#xD;
          -  History of cancer including hematologic malignancy and solid tumors within 10 years of&#xD;
             screening.&#xD;
&#xD;
          -  Known presence of other neurological disorders, clinically significant cardiovascular,&#xD;
             psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal&#xD;
             disease.&#xD;
&#xD;
          -  Rare hereditary problems of galactose intolerance, total lactase deficiency, or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
          -  Hypoproteinemia.&#xD;
&#xD;
          -  Participants with several renal or hepatic disease impairment or Gilbert's Syndrome.&#xD;
&#xD;
          -  Participants with significantly impaired bone marrow function or significant anemia,&#xD;
             leukopenia, neutropenia or thrombocytopenia.&#xD;
&#xD;
          -  Any concomitant disease that may require chronic treatment with systemic&#xD;
             corticosteroids or immunosuppressants during the course of the study.&#xD;
&#xD;
          -  History of alcohol or other drug abuse within 12 months prior to screening.&#xD;
&#xD;
          -  History of or currently active primary or secondary (non-drug-related)&#xD;
             immunodeficiency, including known history of HIV infection.&#xD;
&#xD;
          -  Inability to complete an MRI scan.&#xD;
&#xD;
          -  Adrenocorticotropic hormone or systemic corticosteroid therapy within 4 weeks prior to&#xD;
             screening (inhaled and topical corticosteroids are allowed).&#xD;
&#xD;
          -  Receipt of a live-attenuated vaccine within 6 weeks prior to randomization.&#xD;
&#xD;
          -  Any previous treatment with immunomodulatory or immunosuppressive medication without&#xD;
             an appropriate washout period.&#xD;
&#xD;
        OLE Inclusion Criteria:&#xD;
&#xD;
          -  Completed the Double-Blind Treatment (DBT) phase of the study (remaining on study&#xD;
             treatment; no other Disease-Modifying Therapy (DMT) administered) and who, in the&#xD;
             opinion of the investigator, may benefit from treatment with fenebrutinib.&#xD;
&#xD;
          -  Participants randomized to the teriflunomide treatment arm during the DBT phase must&#xD;
             undergo the ATEP prior to the first administration of open-label fenebrutinib.&#xD;
&#xD;
          -  For female participants of childbearing potential: agreement to remain abstinent&#xD;
             (refrain from heterosexual intercourse) or use contraceptive measures, and refrain&#xD;
             from donating eggs.&#xD;
&#xD;
          -  For male participants: agreement to remain abstinent (refrain from heterosexual&#xD;
             intercourse) or use contraceptive measures, and refrain from donating sperm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GN41851 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Neurology and Spine - Phoenix - Hunt - PPDS</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North County Neurology Associates</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mountain Neurological Research Center; Roaring Fork Neurologt, P.C.</name>
      <address>
        <city>Basalt</city>
        <state>Colorado</state>
        <zip>81621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Neurology of Colorado, LLC</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PA; Research Department</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Highland Park</city>
        <state>Illinois</state>
        <zip>60035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The NeuroMedical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Boster Center for MS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation; MS Center of Excellence</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Neurology</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic PC</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Institute for Neurological Disorders</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Center of Greater Washington</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22182</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IME - Instituto Médico Especializado; Ensayos Clínicos</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Metabolicas (Idim)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto DIABAID</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1061ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas Tucuman; REUMATHOLOGY</name>
      <address>
        <city>San Miguel</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital; Department of Neurology</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Zentrum für Neurologie</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm; Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital; Department of Medicine</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital; Department of Medicine, Division of Neurology</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital; Division of Neurology, Department of Medicine and Therapeutics</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Seconda Università degli Studi; Dip. Assistenziale Integrato Medicina Int-II Clinica Neurologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Seconda Università degli Studi; Dip.Assistenziale Integrato Medicina Int-I Clinica Neurologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I; Centro Sclerosi Multipla DAI Neuroscienze e Salute Mentale</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona</name>
      <address>
        <city>Torrette - Ancona</city>
        <state>Marche</state>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Regina Montis Regalis; SC Neurologia, Centro Sclerosi Multipla</name>
      <address>
        <city>Mondovì (CN)</city>
        <state>Piemonte</state>
        <zip>12084</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOUC Azienda Ospedaliero-Universitaria Careggi; Neurologia 2</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Senese - Presidio Ospedaliero Le Scotte; UOSA Neurologia Sperimentale</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion</name>
      <address>
        <city>Bellavista</city>
        <zip>Callao 2</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia</name>
      <address>
        <city>Lima</city>
        <zip>15003</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional Sede Lima</name>
      <address>
        <city>LIma</city>
        <zip>Lima 01</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASOCIACION CIVIL PORLASALUD; Unidad de Investigación</name>
      <address>
        <city>Miraflores</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HUC; Servico de Neurologia</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santo Antonio dos Capuchos; Servico de Neurologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-050</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Neurologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Beatriz Angelo; Servico de Neurologia</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Santo Antonio; Servico de Neurologia</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Entre o Douro e Vouga E.P.E. - Hospital de São Sebastião; Servilo de Neurologia</name>
      <address>
        <city>Santa Maria Da Feira</city>
        <zip>4520-211</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center of Cardiology and Neurology</name>
      <address>
        <city>Kirov</city>
        <zip>610007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital</name>
      <address>
        <city>St Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge; Servicio de Neurologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron de Madrid; Servicio de Neurologia</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro; Servicio de Neurologia</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall de Hebrón; Servicio de Neurologia. Centre d'Esclerosi Multiple de Catalunya CEMCAT</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Arrixaca; Servicio de Neurología</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena; Servicio de Neurologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital; Neurology</name>
      <address>
        <city>North Dist.</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital; Neurology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Foundation - Linkou - Neurology</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lvov City Clinical Hospital 5'</name>
      <address>
        <city>Lviv</city>
        <state>Chernihiv Governorate</state>
        <zip>79007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Dnipropetrovsk Regional Clinical Hospital n a I I Mechnykov; Neurology dept #1</name>
      <address>
        <city>Dnipro</city>
        <state>Katerynoslav Governorate</state>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Katerynoslav Governorate</state>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zaporizhia City Multispecialty Clinical Hospital #9</name>
      <address>
        <city>Zaporizhzhye</city>
        <state>Katerynoslav Governorate</state>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salutem Medical Center</name>
      <address>
        <city>Vinnytsia</city>
        <state>KIEV Governorate</state>
        <zip>21050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miska Klinichna Likarnia №16</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Tavria Okruha</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ams of Ukraine; Inst. of Neurology, Psychiatry &amp; Narcology</name>
      <address>
        <city>Kharkov</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital; Department of Neurology</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odesa Regional Clinical Hospital; Neurosurgery Department</name>
      <address>
        <city>Odesa</city>
        <zip>65117</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriflunomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

